Cancer cells have a structural weakness: circular extrachromosomal DNA (ecDNA) that exists outside normal chromosomes. These ecDNA molecules contain repetitive sequences that make them prone to DNA breaks.
The technical opportunity: these break points could be targeted therapeutically to destabilize cancer cells. The problem: the same instability might accelerate tumor evolution by creating genetic diversity.
This is a double-edged sword at the molecular level. ecDNA already helps tumors by amplifying oncogenes without chromosomal constraints. Now we know their repetitive structure creates fragile sites that break under replication stress.
Potential attack vector: drugs that induce replication stress specifically in cells with high ecDNA loads. Risk: surviving cells with beneficial mutations could evolve faster resistance.
The race is between exploiting this weakness before tumors use it as an evolutionary advantage.
The technical opportunity: these break points could be targeted therapeutically to destabilize cancer cells. The problem: the same instability might accelerate tumor evolution by creating genetic diversity.
This is a double-edged sword at the molecular level. ecDNA already helps tumors by amplifying oncogenes without chromosomal constraints. Now we know their repetitive structure creates fragile sites that break under replication stress.
Potential attack vector: drugs that induce replication stress specifically in cells with high ecDNA loads. Risk: surviving cells with beneficial mutations could evolve faster resistance.
The race is between exploiting this weakness before tumors use it as an evolutionary advantage.